Erasca Inc
ERASHealthcare|Biotechnology|USA
$18.53
-0.65 (-3.39%)
Tangible Book
$1.27
Upcoming Data Readouts (4)
Nov 2026
Est. completion
P1P2Advanced or Metastatic Solid Tumors
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
NCT04866134n=200
Apr 2028
Est. completion
P3Advanced or Metastatic NRAS-mutant Melanoma
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067n=78
May 2028
Est. completion
P1Metastatic Solid Tumors
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
NCT06983743n=600
Aug 2028
Est. completion
P1Metastatic Solid Tumors
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
NCT07021898n=200
Awaiting Results (3)
Trials past primary completion date but still active — data readout may be imminent.
Feb 2026
P1
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
NCT04670679Aug 2025
P1
A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
NCT05222802Jul 2025
P1
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
NCT05907304